Effectiveness and safety of orelabrutinib combined with rituximab, temozolomide, methotrexate, and cytarabine in intensive chemotherapy-unfit patients with PCNSL in China

Key Points

• Evaluate the effectiveness and safety of orelabrutinib combined with other agents in PCNSL patients unfit for intensive chemotherapy.
• Retrospective study design
• Involved patients with primary CNS lymphoma
• Combination of orelabrutinib, rituximab, temozolomide, methotrexate, and cytarabine
• The ORT-M/A regimen was efficacious
• The treatment was well-tolerated by patients
• Provides a potential therapeutic strategy for unfit PCNSL patients